贝达药业：瑞普晨创自主研发的RGB-5088胰岛细胞注射液治疗1型糖尿病的临床研究已在推进当中

Core Viewpoint - The company is actively engaging in strategic collaborations to address clinical needs in chronic diseases such as hypertension, diabetes, hyperlipidemia, and arthritis, with a focus on stem cell therapy development [2]. Group 1: Strategic Collaborations - The company has formed a strategic partnership with Hangzhou Ruipu Chenchuang Technology Co., Ltd. to develop stem cell therapy [2]. - The collaboration will focus on the technology of inducing differentiation of pluripotent stem cells into pancreatic islet cells [2]. Group 2: Clinical Research Progress - The RGB-5088 pancreatic islet cell injection for the treatment of type 1 diabetes is currently undergoing clinical research [2]. - The company will monitor developments in other areas and will disclose any significant collaborations in a timely manner [2].